تحميل
AMEXHealthcareBiotechnology
أحدث البيانات المتاحة
1.94 US$
−0.01 US$ · -0.51%
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
الإغلاق السابق
1.94 US$
−0.01 US$ · -0.51%
بعد ساعات التداول
1.97 US$
+0.03 US$ · +1.55%
9 أكتوبر، 6:13 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
نطاق اليوم
السعر الحالي 1.94 US$
نطاق 52 أسبوعًا
السعر الحالي 1.94 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
25
مرتفع السعر
المشاعر
63
صعودي
المخاطر
68
مخاطر مرتفعة
الزخم
23
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
نطاق اليوم
السعر الحالي 1.94 US$
نطاق 52 أسبوعًا
السعر الحالي 1.94 US$
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| تكلفة البضاعة المباعة | 15.89 مليون USD | 3.97 مليون USD | 22.47 مليون USD | — | — |
| الربح الإجمالي | −15.89 مليون USD | −3.97 مليون USD | −22.47 مليون USD | — | — |
| البحث والتطوير | 15.89 مليون USD | 18.16 مليون USD | 22.47 مليون USD | 25.36 مليون USD | 23.11 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 8.92 مليون USD | 4.22 مليون USD | 9 مليون USD | 10.71 مليون USD | 13.09 مليون USD |
| نفقات التشغيل | 8.92 مليون USD | 22.38 مليون USD | 9 مليون USD | 36.06 مليون USD | 36.19 مليون USD |
| مصاريف الفوائد | 648.94 ألف USD | 745.67 ألف USD | 675.42 ألف USD | 1.08 مليون USD | 1.15 مليون USD |
| الاستهلاك والإطفاء | 3.89 مليون USD | 3.97 مليون USD | 3.96 مليون USD | 3.83 مليون USD | 2.23 مليون USD |
| الدخل التشغيلي | −24.81 مليون USD | −26.35 مليون USD | −31.48 مليون USD | −36.06 مليون USD | −36.19 مليون USD |
| صافي الدخل | −25.41 مليون USD | −26.92 مليون USD | −32.37 مليون USD | −36.7 مليون USD | −36.36 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
| الإجراء | تاريخ الاستحقاق | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
توزيعات الأرباح | 28 أغسطس 1996 | 0.0083 US$Irregular | — | — |
استحقاق التوزيعات 28 أغسطس 1996
0.0083 US$
Irregular
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI740.24 ألف0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Extended Market ETFVXF139.54 ألف0.00%95.4 مليار USD0.05%235 US$+0.80%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM10 ألف0.01%116.88 مليون USD0.73%15.9402 US$+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
